scispace - formally typeset
W

Wenlei Jiang

Researcher at Princess Margaret Cancer Centre

Publications -  6
Citations -  292

Wenlei Jiang is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Cancer & Transcytosis. The author has an hindex of 4, co-authored 6 publications receiving 231 citations. Previous affiliations of Wenlei Jiang include Ontario Institute for Cancer Research.

Papers
More filters
Journal ArticleDOI

A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics.

TL;DR: PLP offers a biomimetic theranostic nanoplatform for pretreatment stratification using PET and NIR fluorescence imaging and for further customized cancer management via imaging-guided surgery, PDT, or/and potential chemotherapy.
Journal ArticleDOI

Phototheranostic Porphyrin Nanoparticles Enable Visualization and Targeted Treatment of Head and Neck Cancer in Clinically Relevant Models.

TL;DR: It is demonstrated that porphysomes not only enabled fluorescence and photoacoustic imaging of buccal and tongue carcinomas, but also allowed for complete targeted ablation of these tumors.
Journal ArticleDOI

Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma

TL;DR: Size-controlled discoidal and cholesteryl oleated-loaded spherical, intrinsically multimodal porphyrin-lipid nanoparticles targeted glioblastoma via apoE3 and LDLR.
Journal ArticleDOI

Mixed and Matched Metallo-Nanotexaphyrin for Customizable Biomedical Imaging.

TL;DR: A postinsertion methodology to quantitatively insert a variety of metal‐ions into preformed nanotexaphyrins is developed and employed to synthesize a structurally stable, mixed 111indium‐manganese‐nanotexphyrin for dual modal single‐photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI).
Journal ArticleDOI

Correction: Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma.

TL;DR: Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma and provide a novel treatment option for central giant cell granuloma.